Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) formsMarie Ranson, Andrew Katsifis, Rachael Shepherd et al.|Nuclear Medicine and Biology|2012Cited by 4
ANZSNM – ORALS PRESENTATIONSPaula Berghofer, Kara L. Vine, Ivan Greguric et al.|Internal Medicine Journal|2011Cited by 0